RESTOR: mTOR Inhibitor Study for Healthy Older Adults
This study, called RESTOR, is looking at how two drugs, Rapamycin and Everolimus (both mTOR inhibitors), affect aging in healthy older adults. As we age, changes in our cells can lead to health problems. These drugs have shown promise in animal studies for slowing down the aging process. Researchers want to find the best dose and timing of Rapamycin or Everolimus to safely bring certain cell activity levels (mTOR activity) in older adults closer to those seen in younger people. You may be eligible if you are between 65 and 90 years old, in good health, and live in the community. The study is currently unclear on its recruitment status.
- Study design
- This interventional study plans to enroll 194 participants aged 65-90 years. It involves different sub-studies to find the most effective and safe drug, dose, and timing.
- What's involved
- Participants in Sub-study 2 will receive treatment for 6 weeks, followed by a 4-week follow-up. The total duration for Sub-study 3 is approximately 12 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants in Sub-study 2 will have a 4-week follow-up after treatment. For Sub-study 3, follow-up will be for approximately 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
RESTOR: PK/PD mTORi Inhibition in Older Adults
At a glance
Conditions
NCT06658093
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
The University of Texas Health Science Center at San Antonio
San Antonio, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Ellen Kraig, PhD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center at San Antonio
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Pharmacokinetics (PK) of mTOR inhibitor in bloodBaseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)
The levels of the study drug will be measured in whole blood
- PD measure of inhibition of mTOR activity in blood cells - p-rpS6Baseline to study end (approximately 12 months for Aim 2; 12 weeks for Aim 1)
Proteins prepared from PBMCs (peripheral blood mononuclear cells) will be analyzed for phosphorylation of ribosomal protein S6, downstream of mTORC1.
- Level of Soluble Intercellular Adhesion Molecule-1 (sICAM-1)Baseline to study end (approximately 12 months)
The level of soluble (s)ICAM-1 will be measured in serum.